Personalised Medicine Essay

Americans have access to and benefit from one of the most technologically advanced pharmaceutical systems in the world. However, this system is also very strict and tedious. The system this paper will evaluate is the United States Food and Drug Administration (FDA), more specifically, the FDA’s Center for Drug Evaluation and Research (CDER). Although, having access to this system can be frustrating to those that are in the pharmaceutical development industry or those that have illnesses and need the best drugs available in order to cope with their symptoms.

Personalized medicine is currently on the running towards becoming one of the leading advancing fields of health care determined by a person’s individual genetic make-up. It enables an understanding of the molecular framework of the human system so as to augment preventive therapeutic strategies. The move from reactive to preventive health care comes about with the implementation of personalized medicine as an alternative to traditional health care practices.

Our existence, as the most developed species on Earth, relies on intelligence and determination to understand how our body functions and what we can do to help with its constant battle for survival. Diseases that were once deemed rare are becoming extremely common. With no cures, many patients’ lives are endangered. Being born in a generation full of technological advancements, I believe that, with my passion for biology and inquisitiveness for the world of biomedical science, now is the time to engage in this global challenge to develop easier and better ways to live our lives.

Patients Like Me (PLM) is a patient generated research network that strives to improve lives and a research platform in real-time that wishes to advance medicine. On this network, individuals can connect with other who has a common illness or condition, and they can monitor and share their own experiences. In PLM, the information progression data is generated about diseases that can help researchers, medical companies, pharmaceutical companies, and nonprofits, and helps create a more effective care, products, and services. Patient experience with treatments and medication are gathered, which allows treatment efficiency and any side effects to be measured and recorded. If People Like Me were to grow without a General Platform, then the network must continue to add on other niche communities as the group has done in previous

The National Institute of Health (NIH), in coordination with President Obama, has set out in 2015 to tackle these very challenges with their “Precision Medicine Plan”, where the NIH is seeking over one million volunteers to provide health related data for “genetic factors... also the role of environmental exposures and their impact on genetic predispositions”, among other goals. (Steenhuysen, 2015) This project in the growing field of precision medicine is now feasible with the recent developments in the field of both data quality and analysis coupled with leaps in computing power that can back it up. (Warshaw, 2015) The NIH plan, while

However, changing perceptions of prescribers and consumers will be necessary to launch the initiative. The education of providers regarding the therapeutic equivalent and efficacy of generic medications are therapeutic substitutes is very important—prescribers will be the driving force behind adoption of generics over brand-name drugs. The use of e-prescribing provides information regarding cost, formularies and available generics at the fingertips of providers (United States Department of Health and Human Services, 2010).

HC2: With personalized medicine comes many areas of concern, including cost and ethics. It is well known that medical testing of any kind is typically very costly, and personalized medicine is no different. Medical institutions are often slow to adopt new technology and unwilling

The need for new and more effective treatment continues to increase and personalized medicine appears to be the answer to our prayers. With further research personalized medicine could revolutionize pharmaceuticals and to go out on a limb even find a cure for aids and other cancers. But it is too early to have high expectations for a science that has not been deeply explored. It seems that the fantasy of finding a perfect match treatment for each individual has raised support from many institutions including the White House and the FDA. There have been some recent personalized medicine treatments approved by the FDA and this has lead President Obama to bring forward the Precision Medicine Initiative (U.S. Food and Drug Administration), which would give millions in monetary support for research to be conducted on personalized medicine. The issue here is whether

The book The Personalized Medicine Revolution: How Diagnosing and Treating Disease are About to Change Forever is an interesting journey through the evolution of our scientific knowledge and subsequent technologies followed by a final foray into the most current accomplishments in personalized medicine and where it’s going.

In 2010, Francis S. Collins penned The Language of Life: DNA and the Revolution in Personalized Medicine. At that time, he was the director of the Human Genome Project and now currently serves as the head of the National Institutes of Health. Collins is an American geneticist who was influential in discovering the genes responsible for cystic fibrosis and type II diabetes. The Language of Life: DNA and the Revolution in Personalized Medicine begins with a rough overview of genetic principles that will be used in further chapters. The book delves into dominant and recessive genes, single nucleotide polymorphisms (SNPs) and other genetic mutations, as well as, various conditions that arise from the previous genetic circumstances.

The field of medicine recognizes that patients are different. Not only in terms of how a specific disease manifests itself, but also that patients differ in how they respond to certain medications. Precision medicine is a relatively new approach (or medical model) that addresses patient variability. Specifically, precision medicine customizes treatments for a patient based on that patient’s genetics, environment and behavior. While strides have been made towards customizing medical care for patients such as with President Obama’s Precision Medicine Initiative (PMI) announced in 2015, I am skeptical about the role of precision medicine in patient care.

Josko (2014) asserts that the era of personalized medicine is upon us, and that with the completion of the Human Genome Project, and advances in DNA sequencing techniques and

are trying to help this world by advancing more of our precision medicine. This will benefit and

It is an honor for me to lead Pfizer at this important time for both our company and the industry. I’ve spent my entire career at Pfizer and during this time I have seen the industry change and evolve in terms of customers’ needs, regulatory standards and where growth occurs. Among these changes, one of the most important has been the increasing pressure from payers, governments and society to deliver greater value. That’s why I believe there is a fundamental question facing the industry and Pfizer. Simply stated, it is: Do we have a research model that will consistently produce results that improve the lives of patients

Advancements such as genomics, along with other biological technologies, allows for patients to be treated more accurately, effectively, and in ways that better meet an individual’s needs. (2013)Which leads us on to Individualized medicine, this modern medical phenomenon is the tailoring of medical treatment specifically to a patient. There still might be a bit of controversy with the advantages and disadvantages of it, but the ability to provide more accurate treatments along with an early diagnosis in diseases such as cancer, and Pharmacogenomics are essential for human development.